ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Co-stimulation"

  • 2022 American Transplant Congress

    p40 Homodimers Stimulate Graft Dendritic Cells to Produce IL-15 Driving Endogenous Donor-Reactive Memory CD8 T Cell Activation within High-Risk Cardiac Allografts

    H. Tsuda1, A. Valujskikh2, R. Fairchild3

    1Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, 2The Cleveland Clinic Fdn, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH

    *Purpose: Acute allograft injury occurring during the first 1-2 days post-transplant is mediated by graft infiltrating endogenous donor-reactive memory CD8 T cells and requires their…
  • 2022 American Transplant Congress

    Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation

    B. Oh, F. Messner, Y. Guo, G. Brandacher

    Johns Hopkins University School of Medicine, Baltimore, MD

    *Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
  • 2022 American Transplant Congress

    Outcomes After Conversion to Belatacept in Pediatric Kidney Transplantation

    C. Duneton, A. Maisin, E. Cheyssac, H. Dahdouh, V. Baudouin, J. Hogan

    Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France

    *Purpose: Belatacept (CTLA-Ig) is a selective co-stimulation blocker that is associated with reduced dnDSA, improved renal function, and prolonged allograft survival in adult transplant recipients…
  • 2022 American Transplant Congress

    Perioperative IL-6 Blockade Promotes Intra-Graft Regulation and Prevents Costimulation-Blockade Resistant Rejection

    M. Muckenhuber1, K. Mengrelis1, A. M. Weijler1, V. Kainz1, R. Steiner1, H. Regele2, T. Wekerle1

    1Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria, 2Dept. of Pathology, Medical University of Vienna, Vienna, Austria

    *Purpose: Our group has recently shown that CTLA4-Ig monotherapy leads to limited murine heart allograft survival associated with decreased Treg frequencies and early acute T-cell…
  • 2022 American Transplant Congress

    Predictors of Response to Belatacept Conversion in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection

    D. Kumar1, R. Winstead1, H. Iftikhar1, R. Minniti1, S. Khorsandi1, J. Christensen1, I. Yakubu1, I. Moinuddin1, L. Kamal1, P. Halloran2, G. Gupta1

    1Virginia Commonwealth University, Richmond, VA, 2University of Alberta, Edmonton AB, AB, Canada

    *Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of kidney transplant (KT) loss. Current therapies have unclear efficacy and side effects. We…
  • 2022 American Transplant Congress

    T and B Cell Response to 3 Dose Covid Vaccine Series for Kidney Transplant Patients on Belatacept

    J. Christensen1, I. Yakubu2, D. Kumar1, D. Cornett3, M. A. Miller3, M. Altrich3, L. Flebbe-Rehwaldt3, R. Thompson1, G. Gupta1

    1Internal Medicine, Transplant Nephrology, VCUHealth, Richmond, VA, 2Pharmacy, VCUHealth, Richmond, VA, 3Eurofins Viracor, Lee's Summit, MO

    *Purpose: Data shows COVID vaccine response after 2 doses in patients on Belatacept immunosuppression (IS) is low, with reported rates of seroconversion (as measured by…
  • 2022 American Transplant Congress

    Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates

    G. Lassiter, T. Hirose, A. D’Attilio, T. Kawai

    MGH Center for Transplantation Sciences, Boston, MA

    *Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been…
  • 2022 American Transplant Congress

    TNX-1500, an Fc-Modified Anti-cd154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival

    S. Miura1, Z. Abady1, F. Pollok1, M. Ma1, K. Kinoshita1, S. Fogarty2, P. Maguire2, B. Daugherty2, S. Lederman2, R. Pierson III1

    1Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, 2Tonix Pharmaceuticals, Chatham, NJ

    *Purpose: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to replace current clinical immunosuppression. TNX-1500 (TNX) is a novel humanized anti-CD154…
  • 2022 American Transplant Congress

    Cd137 on Host Dendritic Cells Fine-Tunes the Intesity of Donor T Cells in Systemic Alloinmmune Responses

    S. Park1, H. Cho2, B. Kwon3, J. Lee4, H. Park1, J. Park4, K. Park4, K. Yoo4

    1Department of Surgery, University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 2University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 3School of Biological Sciences, University of Ulsan, Ulsan, Korea, Republic of, 4Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, Korea, Republic of

    *Purpose: CD137 is a potent costimulatory receptor for CD8+ T cells but it also regulates dendritic cells (DCs) to suppress immune responses. In this study,…
  • 2022 American Transplant Congress

    TIGIT Agonism Ameliorates Costimulation Blockade-Resistant Rejection by Increasing Quantity and Quality of Graft-Infiltrating Foxp3+ Treg

    C. R. Hartigan, D. Liu, S. Laurie, M. L. Ford

    Emory University Transplant Center, Emory University, Atlanta, GA

    *Purpose: Belatacept-based immunosuppression confers fewer off-target toxicities compared to CNI but comes at a cost of increased incidence and severity of acute rejection, potentially due…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 30
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences